Ying Huang, Chief Executive Officer at Legend Biotech, shared a post on LinkedIn:
“One of the most important questions facing the field today is how to bring cell therapies to more patients.
In a recent conversation with OncoDaily at European Hematology Association (EHA), I shared my perspective on the promise of in vivo CAR-T approaches, the early learnings from LB2501, and why simplifying the treatment journey could help expand access to transformative therapies.
Thank you for the opportunity to discuss the science, the progress we’re seeing, and our continued commitment to advancing innovation for patients.”
More posts featuring Ying Huang.
